Top 10 LARY and LIO Articles of 2024

The “Fascia Taco” for Nasal Septum Perforation Closure—A Retrospective Cohort Study on Success Rates and Patient-Reported Outcomes

By Johannes Bier, MD, Alexandra Klingner, DMD, Rupert Stadlhofer, MD, Christian S. Betz, MD, and Arne Böttcher, MD (doi.org/10.1002/lio2.1248)

Nasal septum perforation is a common condition affecting around 1.2% of the general population and is still considered challenging to treat. Therapeutic strategies range from conservative local treatments and septal button closures to over 40 different surgical approaches. This study aimed to present a novel secure approach.

How to Be a Good Reviewer: A Step-by-Step Guide for Approaching Peer Review of a Scientific Manuscript

By Ahmad R. Sedaghat, MD, PhD, Manuel Bernal-Sprekelsen, MD, PhD, Wytske J. Fokkens, MD, PhD, Timothy L. Smith, MD, MPH, Michael G. Stewart, MD, MPH, and Romaine F. Johnson, MD, MPH (doi.org/10.1002/lio2.1266)

The peer review process is critical to maintaining quality, reliability, novelty, and innovation in scientific literature. The teaching of scientific peer review is rarely a component of formal scientific or clinical training, however, and even the most experienced peer reviewers express interest in continuing education. The objective of this review article is to summarize the collective perspectives of experienced journal editors about how to be a good reviewer in a step-by-step guide that can serve as a resource for the performance of peer review of a scientific manuscript.

Inhaled Fosamprenavir for Laryngopharyngeal Reflux: Toxicology and Fluid Dynamics Modeling

By Alexandra Lesnick, BS, Tina L. Samuels, MS, Donna Seabloom, BS, Beverly Wuertz, BS, Abhilash Ojha, MS, Davis Seelig, DVM, PhD, DACVP, Frank Ondrey, MD, Timothy S. Wiedmann, PhD, Chris Hogan, PhD, Emma Torii, BVSc, MANZCVS, DACVP, Hui Ouyang, PhD, Ke Yan, PhD, Guilherme J. M. Garcia, PhD, Jonathan M. Bock, MD, FACS, and Nikki Johnston, PhD (doi. org/10.1002/lio2.1219)

Approximately 25% of Americans suffer from laryngopharyngeal reflux (LPR), a disease for which no effective medical therapy exists. Pepsin is a predominant source of damage during LPR and a key therapeutic target. Fosamprenavir (FOS) inhibits pepsin and prevents damage in an LPR mouse model. Inhaled FOS protects at a lower dose than oral; however, the safety of inhaled FOS is unknown, and there are no inhalers for laryngopharyngeal delivery. A pre-Good Lab Practice (GLP) study of inhaled FOS was performed to assess safety, and computational fluid dynamics (CFD) modeling was used to predict the optimal particle size for a laryngopharyngeal dry powder inhaler (DPI).